Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429832 · ClinicalTrials.gov registry record · Phase 4
A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department
A Phase 4 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT00429832: Completed Phase 4 study, sponsored by University of New Mexico.
NCT00429832 is a Phase 4 study that has completed, run by University of New Mexico. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429832, a Phase 4 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
Interventions
- DRUG Ondansetron
- DRUG promethazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00429832 record still lists
NCT00429832 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Ondansetron is the first listed.
NCT00429832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00429832 about?
NCT00429832 is a clinical study titled "A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department". This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
What is the current status of trial NCT00429832?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2003-10. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00429832?
The interventions under investigation include: Ondansetron (DRUG), promethazine (DRUG).
Who is sponsoring clinical trial NCT00429832?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00429832's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,289 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia